Discover the study supports the potential of neoadjuvant androgen deprivation therapy as an adjunctive therapy in HRLPC.

A physician survey finds a gap between guidelines and real-world clinical practice in treatment intensification for ...

Prostate cancer is a health issue that impacts individuals worldwide, and choosing the best treatment can be difficult, given ...

Researchers conducted a retrospective study using data from 182 subjects with high-risk recurrent prostate cancers.

Evan Y. Yu, MD, discusses how the ARANOTE study, which evaluated androgen deprivation therapy (ADT) plus darolutamide for metastatic hormone-sensitive prostate cancer (mHSPC), aimed to assess the ...

Evan Y. Yu, MD, discusses how systemic therapy options for newly diagnosed metastatic hormone-sensitive prostate cancer ...

Researchers conducted a post hoc, retrospective, cross-sectional analysis of 182 patients with recurrent prostate cancer ...

EET Orion’s collaboration partner Bayer submits application in China for third indication of darolutamide Orion’s collaboration partner Bayer has submitted an application to the Center of Drug ...

A new study has found that many cases of high-risk nonmetastatic hormone-sensitive prostate cancer may be more advanced than previously thought.

Orion's collaboration partner Bayer has submitted an application to the Center of Drug Evaluation (CDE) of China's National ...

Discover Baduanjin, a traditional Chinese exercise, and a potential complementary therapy for patients with prostate cancer ...

Bayer seeks China NMPA marketing authorization for ARi darolutamide in combo with ADT in patients with metastatic hormone-sensitive prostate cancer: Berlin Wednesday, January 8, 2 ...